1932

Abstract

The basis of the current treatment of rectal cancer is a radical total mesorectal excision of the rectum, and although this provides excellent oncological control, it is associated with morbidity and functional problems in cancer survivors. Organ-preservation alternatives are local excision alone for very early tumors, chemoradiation followed by either local excision of a small tumor remnant or, when there is a complete clinical response, a nonoperative watch-and-wait approach. The functional advantage of these alternatives is clear, but there is some concern about the oncological risk. Although the available studies suggest that with adequate selection and follow-up this risk is small, the evidence is still weak. Because of patients' high interest in preserving quality of life, clinicians should cautiously move ahead and offer the option of organ preservation to patients in a controlled setting while awaiting further evidence.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-062915-021419
2017-01-14
2024-06-25
Loading full text...

Full text loading...

/deliver/fulltext/med/68/1/annurev-med-062915-021419.html?itemId=/content/journals/10.1146/annurev-med-062915-021419&mimeType=html&fmt=ahah

Literature Cited

  1. Rutten HJ, den Dulk M, Lemmens VE. 1.  et al. 2008. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 9:494–501 [Google Scholar]
  2. Juul T, Ahlberg M, Biondo S. 2.  et al. 2014. Low anterior resection syndrome and quality of life: an international multicenter study. Dis. Colon Rectum 57:585–91 [Google Scholar]
  3. Heald RJ, Beets G, Carvalho C. 3.  2014. Report from a consensus meeting: response to chemoradiotherapy in rectal cancer—predictor of cure and a crucial new choice for the patient: on behalf of the Champalimaud 2014 Faculty for ‘Rectal cancer: When NOT to operate’. Colorectal Dis. 16:334–37 [Google Scholar]
  4. van de Velde CJ, Boelens PG, Borras JM. 4.  et al. 2014. EURECCA colorectal: multidisciplinary management: European consensus conference colon and rectum. Eur. J. Cancer 501.e1–1.e34 [Google Scholar]
  5. Glimelius B, Tiret E, Cervantes A. 5.  et al. 2013. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24:Suppl. 6vi81–88 [Google Scholar]
  6. Allaix ME, Arezzo A, Morino M. 6.  2016. Transanal endoscopic microsurgery for rectal cancer: T1 and beyond? An evidence-based review. Surg. Endosc. In press [Google Scholar]
  7. Bach SP, Hill J, Monson JR. 7.  et al. 2009. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br. J. Surg. 96:280–90 [Google Scholar]
  8. Ung L, Chua TC, Engel AF. 8.  2014. A systematic review of local excision combined with chemoradiotherapy for early rectal cancer. Colorectal Dis 16:502–15 [Google Scholar]
  9. Sauer R, Liersch T, Merkel S. 9.  et al. 2012. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J. Clin. Oncol. 30:1926–33 [Google Scholar]
  10. Borschitz T, Wachtlin D, Mohler M. 10.  et al. 2008. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann. Surg. Oncol. 15:712–20 [Google Scholar]
  11. Nair RM, Siegel EM, Chen DT. 11.  et al. 2008. Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum. J. Gastrointest. Surg. 12:1797–805 [Google Scholar]
  12. Lezoche E, Baldarelli M, Lezoche G. 12.  et al. 2012. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br. J. Surg. 99:1211–18 [Google Scholar]
  13. Pucciarelli S, De Paoli A, Guerrieri M. 13.  et al. 2013. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis. Colon Rectum 56:1349–56 [Google Scholar]
  14. Pericay C, Serra-Aracil X, Ocana-Rojas J. 14.  et al. 2015. Further evidence for preoperative chemoradiotherapy and transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer. Clin. Transl. Oncol. 18:666–71 [Google Scholar]
  15. Perez RO, Habr-Gama A, Sao Juliao GP. 15.  et al. 2016. Transanal endoscopic microsurgery (TEM) following neoadjuvant chemoradiation for rectal cancer: outcomes of salvage resection for local recurrence. Ann. Surg. Oncol. 23:1143–48 [Google Scholar]
  16. Garcia-Aguilar J, Renfro LA, Chow OS. 16.  et al. 2015. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 16:1537–46 [Google Scholar]
  17. Verseveld M, de Graaf EJ, Verhoef C. 17.  et al. 2015. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br. J. Surg. 102:853–60 [Google Scholar]
  18. Arezzo A, Arolfo S, Allaix ME. 18.  et al. 2015. Results of neoadjuvant short-course radiation therapy followed by transanal endoscopic microsurgery for T1-T2 N0 extraperitoneal rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 92:299–306 [Google Scholar]
  19. Martens MH, Maas M, Heijnen LA. 19.  et al. 2016. Long-term outcome of organ preservation in 100 clinical complete responders after neoadjuvant treatment for rectal cancer. J. Natl. Cancer Inst. 10812 In press [Google Scholar]
  20. Maas M, Nelemans PJ, Valentini V. 20.  et al. 2010. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11:835–44 [Google Scholar]
  21. Perez RO, Habr-Gama A, Sao Juliao GP. 21.  et al. 2011. Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates. Dis. Colon Rectum 54:545–51 [Google Scholar]
  22. Habr-Gama A, Perez RO, Nadalin W. 22.  et al. 2004. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann. Surg. 240:711–17 [Google Scholar]
  23. Maas M, Beets-Tan RG, Lambregts DM. 23.  et al. 2011. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J. Clin. Oncol. 29:4633–40 [Google Scholar]
  24. Smith JD, Ruby JA, Goodman KA. 24.  et al. 2012. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann. Surg. 256:965–72 [Google Scholar]
  25. Appelt AL, Ploen J, Harling H. 25.  et al. 2015. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol 16:919–27 [Google Scholar]
  26. Breugom AJ, van de Velde CJ. 26.  2015. Is it time for watchful waiting for rectal cancer?. Lancet Oncol. 16:875–76 [Google Scholar]
  27. Glynne-Jones R. 27.  2015. Early rectal cancer: opening the door to change. Lancet Oncol. 16:1449–51 [Google Scholar]
  28. Renehan AG, Malcomson L, Emsley R. 28.  et al. 2016. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 17:174–83 [Google Scholar]
  29. Perez RO. 29.  2016. Complete clinical response in rectal cancer: a turning tide. Lancet Oncol. 17:125–26 [Google Scholar]
  30. Habr-Gama A, Perez RO, Proscurshim I. 30.  et al. 2006. Patterns of failure and survival for nonoperative treatment of stage C0 distal rectal cancer following neoadjuvant chemoradiation therapy. J. Gastrointest. Surg. 10:1319–28 [Google Scholar]
  31. Habr-Gama A, Sabbaga J, Gama-Rodrigues J. 31.  et al. 2013. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?. Dis. Colon Rectum 56:1109–17 [Google Scholar]
  32. Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP. 32.  et al. 2014. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int. J. Radiat. Oncol. Biol. Phys. 88:822–28 [Google Scholar]
  33. Ayloor Seshadri R, Kondaveeti SS, Jayanand SB. 33.  et al. 2013. Complete clinical response to neoadjuvant chemoradiation in rectal cancers: can surgery be avoided?. Hepatogastroenterology 60:410–14 [Google Scholar]
  34. Li J, Liu H, Yin J. 34.  et al. 2015. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study. Oncotarget 6:42354–61 [Google Scholar]
  35. Smith RK, Fry RD, Mahmoud NN. 35.  et al. 2015. Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision. Int. J. Colorectal Dis. 30:769–74 [Google Scholar]
  36. Al-Sukhni E, Attwood K, Mattson DM. 36.  et al. 2015. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann. Surg. Oncol. 23:1177–86 [Google Scholar]
  37. Contin P, Kulu Y, Bruckner T. 37.  et al. 2014. Comparative analysis of late functional outcome following preoperative radiation therapy or chemoradiotherapy and surgery or surgery alone in rectal cancer. Int. J. Colorectal Dis. 29:165–75 [Google Scholar]
  38. Wasserberg N. 38.  2014. Interval to surgery after neoadjuvant treatment for colorectal cancer. World J. Gastroenterol. 20:4256–62 [Google Scholar]
  39. Petrelli F, Sgroi G, Sarti E. 39.  et al. 2016. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann. Surg. 263:458–64 [Google Scholar]
  40. Maas M, Lambregts DM, Nelemans PJ. 40.  et al. 2015. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann. Surg. Oncol. 22:3873–80 [Google Scholar]
  41. Patel UB, Brown G, Rutten H. 41.  et al. 2012. Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Ann. Surg. Oncol. 19:2842–52 [Google Scholar]
  42. Maffione AM, Marzola MC, Capirci C. 42.  et al. 2015. Value of 18F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. Am. J. Roentgenol. 204:1261–68 [Google Scholar]
  43. van der Paardt MP, Zagers MB, Beets-Tan RG. 43.  et al. 2013. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology 269:101–12 [Google Scholar]
  44. Heijnen LA, Lambregts DM, Martens MH. 44.  et al. 2014. Performance of gadofosveset-enhanced MRI for staging rectal cancer nodes: Can the initial promising results be reproduced?. Eur. Radiol. 24:371–79 [Google Scholar]
  45. Perez RO, Habr-Gama A, Pereira GV. 45.  et al. 2012. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: Can they rule out persisting cancer?. Colorectal Dis. 14:714–20 [Google Scholar]
  46. Sloothaak DA, Geijsen DE, van Leersum NJ. 46.  et al. 2013. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br. J. Surg. 100:933–39 [Google Scholar]
  47. Lambregts DM, Maas M, Bakers FC. 47.  et al. 2011. Long-term follow-up features on rectal MRI during a wait-and-see approach after a clinical complete response in patients with rectal cancer treated with chemoradiotherapy. Dis. Colon Rectum 54:1521–28 [Google Scholar]
  48. Garcia-Aguilar J, Chow OS, Smith DD. 48.  et al. 2015. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 16:957–66 [Google Scholar]
  49. Marijnen CA. 49.  2015. Organ preservation in rectal cancer: Have all questions been answered?. Lancet Oncol. 16:e13–22 [Google Scholar]
  50. Beets GL, Figueiredo NL, Habr-Gama A. 50.  et al. 2015. A new paradigm for rectal cancer: organ preservation: introducing the International Watch & Wait Database (IWWD). Eur. J. Surg. Oncol. 41:1562–64 [Google Scholar]
  51. Appelt AL, Ploen J, Vogelius IR. 51.  et al. 2013. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 85:74–80 [Google Scholar]
  52. Smith FM, Al-Amin A, Wright A. 52.  et al. 2016. Contact radiotherapy boost in association with ‘watch and wait’ for rectal cancer: initial experience and outcome from a shared programme between a district general hospital network and a regional oncology centre. Colorectal Dis. In press. doi: 10.1111/codi.13296 [Google Scholar]
  53. Smith JJ, Chow OS, Gollub MJ. 53.  et al. 2015. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 15:767 [Google Scholar]
  54. Ryan JE, Warrier SK, Lynch AC. 54.  et al. 2016. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis 18:234–46 [Google Scholar]
/content/journals/10.1146/annurev-med-062915-021419
Loading
/content/journals/10.1146/annurev-med-062915-021419
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error